Boston Scientific Co. (NYSE:BSX) Shares Sold by New York State Teachers Retirement System

New York State Teachers Retirement System reduced its holdings in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 4.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,285,137 shares of the medical equipment provider's stock after selling 55,891 shares during the period. New York State Teachers Retirement System owned about 0.09% of Boston Scientific worth $114,788,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently made changes to their positions in BSX. Creative Planning boosted its holdings in Boston Scientific by 7.7% in the third quarter. Creative Planning now owns 204,208 shares of the medical equipment provider's stock valued at $17,113,000 after acquiring an additional 14,663 shares in the last quarter. NBC Securities Inc. raised its position in shares of Boston Scientific by 20.5% in the 3rd quarter. NBC Securities Inc. now owns 11,761 shares of the medical equipment provider's stock worth $985,000 after purchasing an additional 2,001 shares during the last quarter. Wolff Wiese Magana LLC raised its position in shares of Boston Scientific by 7,262.5% in the 3rd quarter. Wolff Wiese Magana LLC now owns 2,945 shares of the medical equipment provider's stock worth $247,000 after purchasing an additional 2,905 shares during the last quarter. AAFMAA Wealth Management & Trust LLC raised its position in Boston Scientific by 10.4% in the 3rd quarter. AAFMAA Wealth Management & Trust LLC now owns 32,732 shares of the medical equipment provider's stock worth $2,743,000 after buying an additional 3,077 shares during the last quarter. Finally, Summit Investment Advisory Services LLC purchased a new position in Boston Scientific in the 3rd quarter worth about $212,000. Institutional investors own 89.07% of the company's stock.

Boston Scientific Stock Performance

BSX traded down $0.79 on Tuesday, reaching $105.32. 6,505,334 shares of the stock were exchanged, compared to its average volume of 6,108,297. The company's 50-day moving average price is $96.79 and its 200 day moving average price is $88.61. Boston Scientific Co. has a fifty-two week low of $65.33 and a fifty-two week high of $107.17. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.48 and a quick ratio of 1.02. The firm has a market capitalization of $155.22 billion, a PE ratio of 84.26, a PEG ratio of 2.79 and a beta of 0.80.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 EPS for the quarter, topping analysts' consensus estimates of $0.65 by $0.05. Boston Scientific had a return on equity of 18.11% and a net margin of 11.07%. As a group, sell-side analysts forecast that Boston Scientific Co. will post 2.83 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on BSX shares. Needham & Company LLC reissued a "hold" rating on shares of Boston Scientific in a research report on Thursday, February 6th. Truist Financial upped their target price on shares of Boston Scientific from $100.00 to $110.00 and gave the stock a "buy" rating in a report on Wednesday, December 18th. Morgan Stanley increased their target price on Boston Scientific from $100.00 to $120.00 and gave the stock an "overweight" rating in a research report on Thursday, February 6th. Sanford C. Bernstein increased their target price on Boston Scientific from $92.00 to $100.00 and gave the stock an "outperform" rating in a research report on Thursday, October 24th. Finally, Barclays raised their price target on Boston Scientific from $111.00 to $118.00 and gave the stock an "overweight" rating in a research note on Monday, February 10th. One research analyst has rated the stock with a hold rating, twenty-two have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $107.39.

Insider Activity

In other Boston Scientific news, EVP Arthur C. Butcher sold 14,010 shares of the business's stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $89.27, for a total transaction of $1,250,672.70. Following the completion of the sale, the executive vice president now directly owns 978 shares in the company, valued at approximately $87,306.06. The trade was a 93.47 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Daniel J. Brennan sold 15,087 shares of the business's stock in a transaction that occurred on Wednesday, February 12th. The stock was sold at an average price of $105.07, for a total value of $1,585,191.09. Following the sale, the chief financial officer now owns 241,451 shares of the company's stock, valued at approximately $25,369,256.57. This trade represents a 5.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 88,527 shares of company stock valued at $8,801,626 in the last quarter. 0.50% of the stock is currently owned by company insiders.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.